Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic β-cells to correct diabetes in allogeneic mice

T. Kojaoghlanian, A. Joseph, A. Follenzi, J. H. Zheng, M. Leiser, N. Fleischer, M. S. Horwitz, Teresa P. DiLorenzo, Harris Goldstein

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The effectiveness of genetic engineering with lentivectors to protect transplanted cells from allogeneic rejection was examined using, as a model, type 1 diabetes treatment with β-cell transplantation, whose widespread use has been limited by the requirement for sustained immunosuppressive treatment to prevent graft rejection. We examined whether lentivectors expressing select immunosuppressive proteins encoded by the adenoviral genome early region 3 (AdE3) would protect transplanted β-cells from an alloimmune attack. The insulin-producing β-cell line βTC-tet (C3HeB/FeJ-derived) was transduced with lentiviruses encoding the AdE3 proteins gp19K and RIDα/β. The efficiency of lentiviral transduction of βTC-tet cells exceeded 85%. Lentivector expression of gp19K decreased surface class I major histocompatibility complex expression by over 90%, whereas RIDα/β expression inhibited cytokine-induced Fas upregulation by over 75%. βTC-tet cells transduced with gp19K and RIDα/β lentivectors, but not with a control lentivector, provided prolonged correction of hyperglycemia after transplantation into diabetic BALB/c severe combined immunodeficient mice reconstituted with allogeneic immune effector cells or into diabetic allogeneic BALB/c mice. Thus, genetic engineering of β-cells using gp19K- and RIDα/β-expressing lentiviral vectors may provide an alternative that has the potential to eliminate or reduce treatment with the potent immunosuppressive agents necessary at present for prolonged engraftment with transplanted islets.

Original languageEnglish (US)
Pages (from-to)340-348
Number of pages9
JournalGene Therapy
Volume16
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Immunosuppressive Agents
Proteins
Genetic Engineering
Lentivirus
SCID Mice
Cell Transplantation
Graft Rejection
Major Histocompatibility Complex
Type 1 Diabetes Mellitus
Hyperglycemia
Up-Regulation
Therapeutics
Transplantation
Genome
Insulin
Cytokines
Cell Line
RID

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic β-cells to correct diabetes in allogeneic mice. / Kojaoghlanian, T.; Joseph, A.; Follenzi, A.; Zheng, J. H.; Leiser, M.; Fleischer, N.; Horwitz, M. S.; DiLorenzo, Teresa P.; Goldstein, Harris.

In: Gene Therapy, Vol. 16, No. 3, 2009, p. 340-348.

Research output: Contribution to journalArticle

Kojaoghlanian, T. ; Joseph, A. ; Follenzi, A. ; Zheng, J. H. ; Leiser, M. ; Fleischer, N. ; Horwitz, M. S. ; DiLorenzo, Teresa P. ; Goldstein, Harris. / Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic β-cells to correct diabetes in allogeneic mice. In: Gene Therapy. 2009 ; Vol. 16, No. 3. pp. 340-348.
@article{42322ddb69c9405392d525cc7590bef9,
title = "Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic β-cells to correct diabetes in allogeneic mice",
abstract = "The effectiveness of genetic engineering with lentivectors to protect transplanted cells from allogeneic rejection was examined using, as a model, type 1 diabetes treatment with β-cell transplantation, whose widespread use has been limited by the requirement for sustained immunosuppressive treatment to prevent graft rejection. We examined whether lentivectors expressing select immunosuppressive proteins encoded by the adenoviral genome early region 3 (AdE3) would protect transplanted β-cells from an alloimmune attack. The insulin-producing β-cell line βTC-tet (C3HeB/FeJ-derived) was transduced with lentiviruses encoding the AdE3 proteins gp19K and RIDα/β. The efficiency of lentiviral transduction of βTC-tet cells exceeded 85{\%}. Lentivector expression of gp19K decreased surface class I major histocompatibility complex expression by over 90{\%}, whereas RIDα/β expression inhibited cytokine-induced Fas upregulation by over 75{\%}. βTC-tet cells transduced with gp19K and RIDα/β lentivectors, but not with a control lentivector, provided prolonged correction of hyperglycemia after transplantation into diabetic BALB/c severe combined immunodeficient mice reconstituted with allogeneic immune effector cells or into diabetic allogeneic BALB/c mice. Thus, genetic engineering of β-cells using gp19K- and RIDα/β-expressing lentiviral vectors may provide an alternative that has the potential to eliminate or reduce treatment with the potent immunosuppressive agents necessary at present for prolonged engraftment with transplanted islets.",
author = "T. Kojaoghlanian and A. Joseph and A. Follenzi and Zheng, {J. H.} and M. Leiser and N. Fleischer and Horwitz, {M. S.} and DiLorenzo, {Teresa P.} and Harris Goldstein",
year = "2009",
doi = "10.1038/gt.2008.172",
language = "English (US)",
volume = "16",
pages = "340--348",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic β-cells to correct diabetes in allogeneic mice

AU - Kojaoghlanian, T.

AU - Joseph, A.

AU - Follenzi, A.

AU - Zheng, J. H.

AU - Leiser, M.

AU - Fleischer, N.

AU - Horwitz, M. S.

AU - DiLorenzo, Teresa P.

AU - Goldstein, Harris

PY - 2009

Y1 - 2009

N2 - The effectiveness of genetic engineering with lentivectors to protect transplanted cells from allogeneic rejection was examined using, as a model, type 1 diabetes treatment with β-cell transplantation, whose widespread use has been limited by the requirement for sustained immunosuppressive treatment to prevent graft rejection. We examined whether lentivectors expressing select immunosuppressive proteins encoded by the adenoviral genome early region 3 (AdE3) would protect transplanted β-cells from an alloimmune attack. The insulin-producing β-cell line βTC-tet (C3HeB/FeJ-derived) was transduced with lentiviruses encoding the AdE3 proteins gp19K and RIDα/β. The efficiency of lentiviral transduction of βTC-tet cells exceeded 85%. Lentivector expression of gp19K decreased surface class I major histocompatibility complex expression by over 90%, whereas RIDα/β expression inhibited cytokine-induced Fas upregulation by over 75%. βTC-tet cells transduced with gp19K and RIDα/β lentivectors, but not with a control lentivector, provided prolonged correction of hyperglycemia after transplantation into diabetic BALB/c severe combined immunodeficient mice reconstituted with allogeneic immune effector cells or into diabetic allogeneic BALB/c mice. Thus, genetic engineering of β-cells using gp19K- and RIDα/β-expressing lentiviral vectors may provide an alternative that has the potential to eliminate or reduce treatment with the potent immunosuppressive agents necessary at present for prolonged engraftment with transplanted islets.

AB - The effectiveness of genetic engineering with lentivectors to protect transplanted cells from allogeneic rejection was examined using, as a model, type 1 diabetes treatment with β-cell transplantation, whose widespread use has been limited by the requirement for sustained immunosuppressive treatment to prevent graft rejection. We examined whether lentivectors expressing select immunosuppressive proteins encoded by the adenoviral genome early region 3 (AdE3) would protect transplanted β-cells from an alloimmune attack. The insulin-producing β-cell line βTC-tet (C3HeB/FeJ-derived) was transduced with lentiviruses encoding the AdE3 proteins gp19K and RIDα/β. The efficiency of lentiviral transduction of βTC-tet cells exceeded 85%. Lentivector expression of gp19K decreased surface class I major histocompatibility complex expression by over 90%, whereas RIDα/β expression inhibited cytokine-induced Fas upregulation by over 75%. βTC-tet cells transduced with gp19K and RIDα/β lentivectors, but not with a control lentivector, provided prolonged correction of hyperglycemia after transplantation into diabetic BALB/c severe combined immunodeficient mice reconstituted with allogeneic immune effector cells or into diabetic allogeneic BALB/c mice. Thus, genetic engineering of β-cells using gp19K- and RIDα/β-expressing lentiviral vectors may provide an alternative that has the potential to eliminate or reduce treatment with the potent immunosuppressive agents necessary at present for prolonged engraftment with transplanted islets.

UR - http://www.scopus.com/inward/record.url?scp=62549098121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549098121&partnerID=8YFLogxK

U2 - 10.1038/gt.2008.172

DO - 10.1038/gt.2008.172

M3 - Article

C2 - 19112449

AN - SCOPUS:62549098121

VL - 16

SP - 340

EP - 348

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 3

ER -